Goldman Sachs Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on Maravai LifeSciences (NASDAQ:MRVI) and raises the price target from $7 to $8.
August 08, 2024 | 3:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on Maravai LifeSciences (NASDAQ:MRVI) and raises the price target from $7 to $8.
The raised price target from $7 to $8 by a reputable analyst at Goldman Sachs is a positive signal for investors, indicating potential upside. However, the Neutral rating suggests limited short-term movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100